Imfinzi
durvalumab
APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaOncology
Launch2017-05-01
US LOE2029-05-01
Peak Sales Est$6000M
Formulations[{"id":"imfinzi-iv","doses":"500mg/10mL","route":"IV","setting":"INFUSION_CENTER","frequency":"Every
Mechanism: PD-L1 inhibitor
Expert: Human IgG1 monoclonal antibody that blocks PD-L1 interaction with PD-1 and CD80, restoring T-cell mediated anti-tumor immunity.
Everyday: Helps the immune system recognize and attack cancer cells by blocking a protein that cancer uses to hide.
Targets: ["PD-L1"]
Revenue History
| Period | Revenue ($M) |
|---|
| 2023 | $4,031M |
| 2024 | $4,852M |
| Q1 2025 | $1,320M |
| Q2 2025 | $1,410M |
| Q3 2025 | $1,480M |
Programs (4)
| Indication | Stage | Key Study | Regional Status |
|---|
| NSCLC (unresect) | APPROVED | PACIFIC | [{"stage":"APPROVED","region":"US","approval_date":"2018-02-16"},{"stage":"APPRO |
| NSCLC (resect) | APPROVED | AEGEAN | [{"stage":"APPROVED","region":"US","approval_date":"2020-03-27"},{"stage":"APPRO |
| ES-SCLC | APPROVED | CASPIAN | [{"stage":"APPROVED","region":"US","approval_date":"2020-03-27"},{"stage":"APPRO |
| BTC | APPROVED | TOPAZ-1 | [{"stage":"APPROVED","region":"US","approval_date":"2022-09-02"},{"stage":"APPRO |
Upcoming Catalysts (4)
Imfinzi + Imjudo - Locoregional HCC - Ph3 - Topline
H1 2026
Imfinzi ± Imjudo - MIBC - Ph3 - Topline
H1 2026
Datroway + Imfinzi - NSCLC - Ph3 - Topline (TROPION-Lung08)
H1 2026
Imfinzi - Early HCC - Ph3 - Topline
H2 2026
Notes
PD-L1 antibody. Multiple indications.
Data from Supabase · Updated 2026-03-24